Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival

Share this content:
At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.
At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.
The following article features coverage from the San Antonio Breast Cancer Symposium (SABCS) 2017 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Long-term disease-free survival (DFS) and overall survival (OS) are similar for women with early stage (cT1-T2 N0) breast cancer and micrometastases in the sentinel lymph nodes only who undergo axillary dissection (AD) vs those who do not, according to findings presented at the 2017 San Antonio Breast Cancer Symposium.1

“Our findings are fully consistent with those of the Z0011 trial, which after 10 years found no differences between the AD and no AD groups for any endpoint in patients with moderate disease burden in the axilla undergoing conservative breast surgery,” said study coauthor Viviana Galimberti, MD, of the European Institute of Oncology in Italy.

For the phase 3 IBCSG 23-01 study, researchers compared DFS in patients who were randomly assigned to undergo or forego AD. At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.

Of 934 women enrolled, outcomes were measured for 467 and 464 women in the non-AD and AD groups, respectively.

The 10-year DFS rates were similar in both study arms (77% for non-AD vs 75% for AD; hazard ratio [HR], 0.85; 95% CI: 0.65-1.11; P = .24). There were 2 ipsilateral axillary DFS events among women who underwent mastectomy (1 patient each in the AD and non-AD study arms).

OS was also similar between the study arms (10-year OS, 91% for non-AD vs 88% for AD; HR, 0.77; 95% CI: 0.57-1.07; P = .20).

Subgroup analyses for tumor size, estrogen receptor status, progesterone receptor status, tumor grade, and type of surgery (mastectomy or breast-conserving) did not identify any patient subgroup for which AD offered a DFS advantage.

“No AD is now standard treatment in early breast cancer when the sentinel node is only minimally involved,” Dr Galimberti concluded.

Read more of Cancer Therapy Advisor's coverage of the San Antonio Breast Cancer Symposium (SABCS) 2017 meeting by visiting the conference page.

Reference

  1. Galimberti V, Cole BF, Viale G, et al. Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial. Oral presentation at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs